In chronic myeloid leukemia (CML), recombinant antibodies targeting IL-1 receptor antagonist (IL-1RA) and IL-1 receptor accessory protein (IL1RAP) can block IL-1 signaling in CML leukemia stem cells (LSCs) and inhibit their growth (85, 86). Here, IL1RAP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.